Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McMaster University
$105,000.00
Reversing Carbapenemase Resistance through the Discovery and Characterization of Novel Natural Product Beta-Lactamase Inhibitors
EF 2013-14
Résumé
The development of antibiotics as a therapeutic for bacterial infection revolutionized has revolutionized medicine over the past century. Both routine and life-saving medical procedures rely on the use of antibiotics, let alone the myriad assortment of bacterial infections they treat. Notwithstanding, bacteria have evolved elegant mechanisms of resistance to the effects of antibiotic therapy. This has driven the discovery and development of many different antibiotics but it is the beta-lactam class of antibiotics (comprised largely of penicillins, cephalosporins, and carbapenems) that accounts for nearly 60 percent of sales in the US. Bacteria use enzymes, called beta-lactamases, to inactivate these antibiotics, rendering them useless for treatment of infection. In response, researchers have developed increasingly effective beta-lactam antibiotics. This has culminated in the carbapenems, considered an antibiotic of last resort for many multidrug resistant bacterial infections. In recent years we have seen the emergence of carbapenem-resistant Enterobacteriaceae (CRE), a group of infectious microorganisms that have become resistant to virtually all currently used antibiotics including precious carbapenems. These organisms have been labelled an 'urgent threat' to public health by the United States Centers for Disease Control and Prevention, making them one of three classes of microorganisms receiving the highest threat level recognized. My project aims to discover and develop novel compounds that will be able to inhibit the action of these enzymes used by CRE, thereby restoring the activity of beta-lactam antibiotics. We have met with initial success in treating organisms that express New Delhi metallo-beta-lactamase 1 (NDM-1) using a novel compound we have discovered and filed a provisional patent on. We will now expand our efforts to target other important enzymes that contribute to this burden on healthcare systems in Canada and worldwide.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
307800
Name
King Andrew M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Reversing Carbapenemase Resistance through the Discovery and Characterization of Novel Natural Product Beta-Lactamase Inhibitors
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Antibiotic Resistance; Beta-Lactamase; Cre; Enzymology; Kpc-2; Microbiology; Natural Products; Ndm-1; Screening
Abstract
The development of antibiotics as a therapeutic for bacterial infection revolutionized has revolutionized medicine over the past century. Both routine and life-saving medical procedures rely on the use of antibiotics, let alone the myriad assortment of bacterial infections they treat. Notwithstanding, bacteria have evolved elegant mechanisms of resistance to the effects of antibiotic therapy. This has driven the discovery and development of many different antibiotics but it is the beta-lactam class of antibiotics (comprised largely of penicillins, cephalosporins, and carbapenems) that accounts for nearly 60 percent of sales in the US. Bacteria use enzymes, called beta-lactamases, to inactivate these antibiotics, rendering them useless for treatment of infection. In response, researchers have developed increasingly effective beta-lactam antibiotics. This has culminated in the carbapenems, considered an antibiotic of last resort for many multidrug resistant bacterial infections. In recent years we have seen the emergence of carbapenem-resistant Enterobacteriaceae (CRE), a group of infectious microorganisms that have become resistant to virtually all currently used antibiotics including precious carbapenems. These organisms have been labelled an 'urgent threat' to public health by the United States Centers for Disease Control and Prevention, making them one of three classes of microorganisms receiving the highest threat level recognized. My project aims to discover and develop novel compounds that will be able to inhibit the action of these enzymes used by CRE, thereby restoring the activity of beta-lactam antibiotics. We have met with initial success in treating organisms that express New Delhi metallo-beta-lactamase 1 (NDM-1) using a novel compound we have discovered and filed a provisional patent on. We will now expand our efforts to target other important enzymes that contribute to this burden on healthcare systems in Canada and worldwide.
Competitiondate
201310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
King, Andrew M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~